This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Renal disease				
Renal damage	Adenosine A ₂ receptor (ADORA ₂)	<p><i>In vitro</i> and mouse studies suggest ADORA₂ agonist-treated dendritic cells (DCs) could help treat acute kidney injury. Mice with <i>Adora₂^{-/-}</i> DCs showed greater susceptibility to kidney injury than mice with DCs deficient in other adenosine receptors. In wild-type mice, ADORA₂ agonist-treated DCs given before or 1–6 hours after kidney injury protected kidney function, whereas untreated DCs did not. Next steps could include optimizing the cell-based therapy protocol. Addex Therapeutics Ltd.'s A2A PAM, a positive allosteric modulator of ADORA₂, is in discovery stages to treat psoriasis and osteoarthritis.</p> <p>SciBX 5(43); doi:10.1038/scibx.2012.1146 Published online Nov. 1, 2012</p>	Patent and licensing status unavailable	<p>Li, L. <i>et al. J. Clin. Invest.</i>; published online Oct. 24, 2012; doi:10.1172/JCI63170 Contact: Li Li, University of Virginia, Charlottesville, Va. e-mail: ll3m@virginia.edu</p>